LMPTP inhibitor 1|cas 1908414-82-3|DC Chemicals

Cas No.:	1908414-82-3
Chemical Name:	N,N-diethyl-4-[4-[[3-(1-piperidinyl)propyl]amino]-2-quinolinyl]-benzamide
SMILES:	C(N(CC)C(=O)C1C=CC(C2C=C(NCCCN3CCCCC3)C3C(=CC=CC=3)N=2)=CC=1)C
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

LMPTP inhibitor 23 is a potent, selective, orally bioavailable low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 0.8 uM; displays exquisite selectivity for LMPTP versus other PTPs including PTP1B, shows greater potency on LMPTP-A versus LMPTP-B; inhibits uncompetitively LMPTP with Ki of 846 nM, substantially increases HepG2 IR phosphorylation after insulin stimulation and reversess diabetes in mice without causing overt toxicity or weight loss.

References:

References 1. Stanford SM, et al. Nat Chem Biol. 2017 Jun;13(6):624-632. View Related Products by Target Protein Phosphatase/PTP

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC71995	PSB-06126	PSB-06126 is a selective nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with the Ki values of 0.33 μM for rat NTPDase 1, 19.1 μM for NTPDase 2 and 2.22 μM for NTPDase 3, respectively.
DC70739	RMC-4630	RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway.
DC70502	IACS-15414	IACS-15414 (IACS 15414) is a potent, selective, orally bioavailable SHP2 inhibitor with IC50 of 122 nM; IACS-15414 potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo. IACS-15414 potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth. IACS-15414 had excellent PK properties across species but a narrow hERG window.
DC11021	KY-226	KY-226 (KY226) is a potent, allosteric, orally active inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 uM (human PTP1B), does not exhibit PPARγ agonist activity.
DC10088	TPI-1	TPI-1 is a potent and selective SHP-1 inhibitor effective at low nanomolar levels.
DC9737	SHP099 hydrochloride	SHP099 is a selective, orally bioavailable, and efficacious SHP2 inhibitor with IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM.
DC10004	SHP099 free base	SHP099 is a selective, orally bioavailable, and efficacious SHP2 inhibitor with IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM.
DC12051	RMC-4550	RMC-4550 (RMC4550) is a potent, selective, allosteric inhibitor of SHP2 with IC50 of 0.58 nM (full-length SHP2 enzyme), suppresses pERK signaling in Calu-1 cells with IC50 of 7 nM.
DC10878	Raphin1	Raphin1 is an orally available selective phosphatase inhibitor improves proteostasis and diminishes deficits in a mouse model of Huntington’s disease.
DC9999	NQ301	NQ301 is a selective CD45 inhibitor (IC50 = 200 nM). Exhibits >200-fold selectivity for CD45 over six related protein tyrosine phosphatases.